Artificial intelligence (AI) cerebrovascular software developer RapidAI expanded its market reach and grew its client base to 60 countries in 2020. It also raised $25 million in funding to support this expansion.
The company increased its scope from stroke to aneurysm, in part by acquiring EndoVantage, thus paving the way for further expansion into the vascular imaging market. It processed more than 1 million stroke imaging scans, a 1,900% increase over 2017, and partnered with therapy products firm Penumbra in an effort to expand into the pulmonary embolism market.
The U.S. Food and Drug Administration cleared the company's Rapid Aspects software for neuroimaging analysis on noncontrast CT, as well as its Rapid LVO software for detecting large-vessel occlusions, it said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
